Key result
End-of-treatment PET-negative status in patients with primary mediastinal large B-cell lymphoma treated with R-CHOP was associated with a 5-year time to progression of 90% versus 71% for PET-positive cases.
Why the study?
Although cure rates for PMBCL have improved with rituximab, the optimal primary therapy and the role of consolidative radiotherapy remain ill-defined.
Does a PET-adapted approach to guide radiotherapy maintain outcomes compared to routine radiotherapy in adults with PMBCL treated with R-CHOP?
Cohort (n=159)
Does a PET-adapted approach to guide radiotherapy maintain outcomes compared to routine radiotherapy in adults with PMBCL treated with R-CHOP?
Absolute Event Rate: 90% vs 71%
A PET-adapted approach after R-CHOP for PMBCL safely reduces the use of consolidative radiotherapy without compromising survival.
No takes yet. Share an insight, caveat, or question.
May support reduced RT use after R-CHOP in PMBCL without compromising outcomes; leaves open randomized confirmation of PET guidance.
Hayden et al. (2020) conducted a cohort in Primary mediastinal large B-cell lymphoma (PMBCL) (n=159). End-of-treatment PET-negative scan vs. End-of-treatment PET-positive scan was evaluated on 5-year time to progression (TTP). End-of-treatment PET-negative status in patients with primary mediastinal large B-cell lymphoma treated with R-CHOP was associated with a 5-year time to progression of 90% versus 71% for PET-positive cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: